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PTX animals increased FGF23 and cal-
citriol and normalized serum phosphate 
levels. Several observations had already 
suggested that PTH could stimulate skel-
etal FGF23 production. Administration 
of (1-34)PTH to healthy individuals 
increased serum FGF23. Moreover, con-
stitutively activated PTHR1 in Jansen ’ s 
disease, which can be considered as a 
primary hyperparathyroidism with high 
PTH and hypophosphatemia, showed 
elevated FGF23. 9 Similarly, high FGF23 
is oft en seen in secondary hyperparathy-
roidism and can predict its severity and 
its resistance to vitamin D therapy 
in chronic kidney disease patients. 10 
In the same patients, serum FGF23 sig-
nifi cantly declined aft er parathyroidec-
tomy. L ó pez  et al. 8 confi rm and extend 
these previous fi ndings, demonstrating 
that PTH, either directly or indirectly via 
calcitriol, is necessary for skeletal 
FGF23 production. 
 Probably, one of the most interesting 
fi ndings of this study is the lack of eff ect 
of FGF23 on urinary and serum phos-
phate in the absence of PTH. PTX animals 
receiving physiological doses of calcitriol 
had high FGF23 but did not normalize 
serum phosphate, implying that, at least 
in the kidney, there was a key factor 
 regulated by PTH that was required for 
the phosphaturic action of FGF23. Th is 
factor was certainly klotho, as the authors 
found a reduction of klotho expression in 
the kidneys of PTX animals. Importantly, 
renal klotho expression was restored to 
normal levels aft er PTH supplementation, 
allowing FGF23 to exert its phosphaturic 
action and the normalization of serum 
phosphate levels. 
 In summary, the study by L ó pez  et al. 8 
shows that PTH is necessary in main-
taining normal circulating FGF23 levels, 
that changes in calcitriol levels unques-
tionably play a role in the stimulatory 
eff ect of PTH on FGF23, and that PTH 
regulates klotho expression in the kidney 
and thereby the phosphaturic eff ect of 
FGF23. It confi rms the existence of three 
feedback loops, involving parathyroid 
glands, bone, and kidney, regulating 
serum phosphate concentration ( Figure 
1 ) and opens a number of areas for clin-
ical and experimental research in the 
fi eld of phosphate homeostasis. 
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 Since 1883, when Ringer discovered 
that a trace amount of Ca 2  +   from tap 
water was suffi  cient to induce contrac-
tion of a frog ’ s heart, the role of Ca 2  +   in 
regulating physiological functions has 
been continually investigated. We now 
know that appropriate concentrations 
of extracellular and intracellular Ca 2  +  
are vital to the survival of all organisms 
from the simplest unicellular organism 
to mammals and that highly regulated 
processes are required to provide con-
stant and appropriate quantities of the 
ion to cells and tissues. Therefore, 
sophisticated mechanisms enable cells 
to detect minor changes in extracellular 
Ca 2  +   content to counteract and modify 
their behavior accordingly. 
 In major organisms, Ca 2  +   has to be 
controlled both systemically and locally, 
and in mammals, the control of systemic 
calcium homeostasis is mediated by the 
calcium-sensing receptor (CaSR). 
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 Besides its primary function in maintaining systemic calcium 
homeostasis, the calcium-sensing receptor (CaSR) is expressed by many 
cell types, with different, sometimes opposite, regulatory functions. 
Novel work from Oh and collaborators shows that activation of CaSR 
in podocytes has prosurvival effects and protects the cell from 
puromycin aminonucleoside damage. Given that the cellular 
consequences of CaSR activation are largely context-dependent, 
further studies will be required to elucidate its precise role in podocyte 
physiology and pathophysiology. 
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 First cloned from the parathyroid and 
the kidney, CaSR is a G protein-coupled 
receptor encoded by one gene, located in 
humans on chromosome 3. Its non-
 redundant role in maintaining appropri-
ate levels of systemic calcium is well 
demonstrated by human diseases 
due to  CaSR  mutations; heterozygous 
and homozygous  CaSR -inactivating 
mutations cause familial hypocalciuric 
hypercalcemia and neonatal severe 
hyperparathyroidism, respectively. On 
the other hand, gain-of-function muta-
tion of  CaSR leads to autosomal domi-
nant hypoparathyroidism. 
 CaSR can be activated by a series of ago-
nists that are classifi ed, depending on their 
action, into type I and type II. Type I ago-
nists, or true agonists, are divalent cations 
(namely, Ca 2  +   and Mg 2  +   ), polycations 
(such as gadolinium, polyarginine, poly-
lysine, and neomycin), and   -amyloid 
peptides, which directly activate the recep-
tor. Type II agonists are better referred to 
as modulatory substances, because they 
allosterically increase the receptor ’ s 
 calcium affi  nity, thereby requiring extra-
cellular calcium for their action. Physio-
logical type II agonists are, for instance, 
spermine, spermidine, aromatic amino 
acid residues, extracellular pH, and ionic 
strength, meaning that activation of CaSR 
has to be considered always in the context 
of the cell microenvironment. Calcimi-
metics belong to the type II agonist  family; 
they are positive allosteric CaSR modula-
tors, currently in use for the treatment of 
hyperparathyroidism secondary to renal 
failure. Finally, the receptor can be allos-
terically negatively modulated by so-
called calcilytics, of potential utility to 
treat osteoporosis. 
 Aft er the fi rst expression analyses con-
ducted on parathyroid gland and kidney, 
the presence of CaSR has been demon-
strated in several tissues and cells not 
related to systemic calcium homeostasis, 
and its function has been largely investi-
gated, revealing that the receptor regulates 
a series of diverse, sometimes opposite, 
cellular functions. 
 If downstream eff ects can be highly dif-
ferent, the fi rst steps of receptor activation 
are common; stimulation of the receptor 
evokes an increase in free ionized intracel-
lular Ca 2  +   concentration, either through 
phospholipase C-dependent activation of 
inositol trisphosphate-sensitive stores or 
through activation of Ca 2  +   -sensitive 
 cation channels. 
 To list some examples, the receptor has 
been implicated in gastrin and gastric acid 
secretion, keratinocyte diff erentiation, 
promotion or prevention of tumor growth 
(depending on the type of cancer), and 
insulin secretion from pancreatic islet 
  -cells, among others. CaSR has also been 
linked to infl ammatory states, both with 
an elevation in cytokine production upon 
its stimulation, and with an upregulation 
of its expression when exposed to an 
infl ammatory environment. 
 From all these studies in diff erent sys-
tems a common concept emerges: the 
eff ects of CaSR activation are largely con-
text-dependent, because the cellular envi-
ronment has profound infl uences on its 
responses to ligands. This behavior is 
common for G protein-coupled receptors 
and is called  ‘ conditional effi  cacy, ’ the abil-
ity of a receptor to sense not only the 
direct ligand but also the environment 
and to qualitatively and quantitatively 
adapt the answer(s) accordingly. 
 Th e presence of CaSR in the glomerulus 
is still under debate. Th e fi rst evidence of a 
glomerular mRNA transcript of CaSR was 
shown in the rat kidney by Riccardi  et al. 
in 1996 (ref.  1 ) but was not confi rmed by 
Yang  et al. in 1997 (ref.  2 ), and in a recent 
review, Riccardi  et al. show negative CaSR 
immunostaining in human glomeruli. 3 In 
2005 Kwak  et al. studied CaSR expression 
and activity in mesangial cells, 4 and in 
2008 the presence of the receptor on podo-
cytes was shown for the fi rst time, by  in situ 
hybridization and immunohistochemistry, 
on rat renal tissue by Piecha  et al. 5 
 Now, the same group from Heidelberg 
(Oh  et al. , 6 this issue) proceeds into the 
investigation and analyzes the potential 
role of CaSR in podocytes by a series of 
 in vitro and  in vivo studies aimed at clari-
fying some of the intracellular pathways 
activated by the receptor. 
 Th e authors show that CaSR stimula-
tion by the calcimimetic R-568 of normal 
podocytes activates a prosurvival pathway 
( Figure 1 ), by inducing ERK1 / 2 phospho-
rylation and subsequent CREB phospho-
rylation. Th ey also describe other eff ects, 
all in the same prosurvival direction, such 
as activation of pBAD and Bcl-xL, increase 
of Rho kinase activity, and decrease of 
cyclic adenosine monophosphate content. 
According to these data, activation of 
these intracellular pathways explains the 
protective eff ect exerted by R-568, which 
reduces apoptosis in podocytes incubated 
with puromycin aminonucleoside (PAN) 
and ameliorates podocyte cytoskeleton 
when damage is induced by either PAN or 
cytochalasin. Subsequently, the authors 
observe  in vivo protecting eff ects of R-568 
against PAN nephropathy, which occur 
when the molecule is administered either 
before or 2 – 4 days aft er PAN injection. 
 Th ere is no doubt that podocytes need 
tight calcium control. Mutations in the 
 TRPC6 calcium channel (transient recep-
tor potential channel 6) gene have been 
associated with familiar forms of focal and 
segmental glomerulosclerosis. In addition, 
acquired glomerular diseases, especially 
membranous nephropathy, are associated 
with increased expression levels of 
TRPC6. 7 Our group has recently shown 
that podocytes express another calcium 
channel, previously thought to belong only 
to neuronal cells, the ionotropic  N -methyl-
 d -aspartate (NMDA) receptor, whose 
blockade causes podocyte cytoskeletal 
damage and increased proteinuria. 8 
 Interestingly, CaSR is also expressed by 








 Figure 1  |  The intracellular pathways 
activated in healthy podocytes upon 
stimulation of CaSR by calcimimetics, 
according to the results of Oh  et al. 6 
CaSR, calcium-sensing receptor. 
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several areas of the brain and cerebellum, 
where it overlaps with group I metabo-
tropic glutamate receptors, especially 
Grm1. Th is proximity between CaSR and 
Grm1 has been analyzed, because amino 
acids and calcium reciprocally infl uence 
both receptors. Heterodimers of CaSR and 
Grm1 have also been demonstrated that 
can lead to signal enhancement, changes 
in sensitivity to agonists, and diff erences 
in traffi  cking of the receptors themselves. 
 Our group has described the use by 
podocytes of a neuron-like system of sig-
naling, 9 and we have recently observed that 
mice lacking one or both alleles of Grm1 
have podocyte alterations and higher pro-
teinuria than the corresponding wild 
type. 10 In podocytes, Grm1 colocalizes 
with nephrin, and its silencing causes 
disappearance of nephrin from podocyte 
processes and alters podocyte actin 
cytoskeleton. In view of these data, the rela-
tionship and the potential reciprocal infl u-
ences of CaSR and Grm1 at the glomerular 
fi ltration barrier could be worth studying. 
 Given the context-dependent nature of 
CaSR, the promising experimental results 
obtained by Oh  et al. 6 cannot be easily 
generalized, and experiments on primary 
podocytes and on diff erent experimental 
models will be required before better 
knowledge can be gained on the role of 
the receptor in the glomerulus. An induc-
ible podocyte-specific CaSR knockout 
model would be ideal to shed further light 
on the activity of the receptor at the 
glomerular fi ltration barrier. 
 The potential CaSR expression by 
mesangial cells needs further investigation 
as well. Previous data showed that  activation 
of CaSR induces mesangial-cell prolifera-
tion, certainly not a desirable eff ect in most 
human glomerular disease settings. 
 In summary, the data published by Oh 
 et al. open an intriguing chapter of inves-
tigation on podocyte biology that may 
extend our knowledge of the mechanisms 
used by this cell to control its intracellular 
calcium content and to properly respond 
to microenvironmental changes. 
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 Bone marrow-derived neutrophils repre-
sent the most abundant circulating leuko-
cyte population and are rapidly recruited 
to sites of tissue injury and microbial inva-
sion. Th ey play an essential, non-redundant 
role in wound healing and in the innate 
immune response to bacterial and fungal 
infection, as evidenced by the severity of 
neutrophil-specific inherited disorders 
such as chronic granulomatous disease. 1 
Neutrophil effector functions include 
phagocytosis and the triggered release of a 
broad range of bioactive products, includ-
ing reactive oxygen species, antimicrobial 
peptides, enzymes, cytokines, and chem-
okines — many of which are highly destruc-
tive of microbes and surrounding tissue 
alike. 1 Although frequently perceived as 
 ‘ blunt instruments ’ in terms of immuno-
logical specifi city, neutrophils are, in fact, 
highly regulated, interact extensively with 
other innate and adaptive immune cells, 
and participate actively in infl ammatory 
resolution and tissue repair. 1,2 
 It has been appreciated for some time 
that end-stage renal disease is associated 
see original article on page 493
 Defective neutrophil rolling and 
transmigration in acute uremia 
 Jana  Pindjakova 1 and  Matthew D.  Griffin 1 
 Circulating neutrophils are essential for innate immunity and 
undergo rapid, stepwise adhesion to and transmigration through the 
endothelium following tissue injury and microbial invasion. Neutrophil 
dysfunction may contribute to morbidity and mortality in acute kidney 
injury but has not frequently been studied at a mechanistic level. 
Rossaint  et al. provide experimental evidence in mice and humans 
that acute uremia causes discrete intracellular signaling abnormalities 
that interfere with specific stages of neutrophil trafficking during 
inflammation. 
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